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Abstract
The Asia Pacific region, home to two-thirds of the world’s population and ten of the least developed countries, is
considered a regional hot-spot for the emergence and spread of antimicrobial resistance (AMR). Despite this, there
is a dearth of high-quality regional data on the extent of AMR. Recognising the urgency to close this gap, Singapore
organised a meeting to discuss the problems in the region and frame a call for action. Representatives from across
the region and beyond attended the meeting on the “Antimicrobial Resistance in the Asia Pacific & its impact on
Singapore” held in November 2018. This meeting report is a summary of the discussions on the challenges and
progress in surveillance, drivers and levers of AMR emergence, and the promising innovations and technologies that
could be used to combat the increasing threat of AMR in the region. Enhanced surveillance and research to provide
improved evidence-based strategies and policies are needed. The major themes that emerged for an action plan are
working towards a tailored solution for the region by harnessing the One Health approach, enhancing inter-country
collaborations, and collaboratively leverage upon new emerging technologies. A regionally coordinated effort that is
target-driven, sustainable and builds on a framework facilitating communication and governance will strengthen the
fight against AMR in the Asia Pacific region.
Keywords: Asia Pacific, Singapore, One Health, Global Health, Global Mobility, Travel, Drug Resistance, Antimicrobial
Resistance
Introduction
Antibiotics have revolutionised modern medicine and
facilitated advances in transplantation, chemotherapy and
surgery, while drastically reducing the mortality and mor-
bidity from infectious diseases. The ever-increasing demand
for antibiotics in healthcare is evident in the 65% increase
in global consumption from 21.1 billion to 34.8 billion daily
doses from 2000 to 2015 [1]. Besides human healthcare, an-
tibiotics are used for the prevention and treatment of dis-
eases in food-producing animals in the agriculture and
aquaculture industries, as well as for growth promotion.
Medically-important antibiotics accounted for 51% of all
domestic sales of antibiotics approved for food-producing
animals in the United States (US) in 2017 [2]. The wide-
spread use of antimicrobials has hastened the development
of antimicrobial resistance (AMR) through increased selec-
tion pressure for genes that confer mechanisms to reduce
the effectiveness of antibiotics. This led to the emergence of
multi (MDR) and extensively drug-resistant (XDR)
pathogens such as Mycobacterium tuberculosis (MTB),
carbapenem-resistant Enterobacteriaceae (CRE), XDR
Pseudomonas aeruginosa and Acinetobacter baumannii and
methicillin-resistant Staphylococcus aureus (MRSA). These
pathogens are part of the World Health Organisation
(WHO)’s priority list published in 2017, widely known as
the “dirty dozen” that pose a significant threat to human
health [3]. Recognising the potential scale and enormity of
the impact of AMR, the Heads of States at the United Na-
tions General Assembly passed a resolution in September
2016 to reaffirm their commitment to tackling the rising
threats of AMR [4].
The Asia Pacific region (APAC), home to two-thirds of
the world’s population and ten of the least developed coun-
tries [5, 6], is highly vulnerable to the threats of AMR.
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AMR undermines efforts in improving the health systems
and health security in APAC and threatens the overall
growth potential of the region. In light of the growing
threat of AMR in the region, Lee Kong Chian School of
Medicine (LKCMedicine) together with Saw Swee Hock
School of Public Health; Singapore-MIT Alliance for Re-
search and Technology; National Centre for Infectious Dis-
eases; DSO National Laboratories; and the Ministry of
Health, Singapore organised a meeting titled “Antimicrobial
Resistance (AMR) in the Asia Pacific & its impact on
Singapore”. The meeting was held from 13 to 14 November
2018 at the LKCMedicine in Singapore to coincide with the
annual World Antibiotic Awareness Week.
This report summarises the information and insights
shared by 26 experts who represented the academic, indus-
try and government sectors from Papua New Guinea,
Timor Leste, Indonesia, Thailand, Cambodia, Myanmar,
India, Singapore, US and the United Kingdom. This report
consists of three sections, namely, the challenges and pro-
gress in surveillance, drivers and levers of AMR, and poten-
tial innovations and technologies to combat the increasing
threat in the region. We will present potential solutions
and a roadmap as discussed during the meeting.
Global antimicrobial resistance
Drug-resistant pathogens have been found in every contin-
ent; however, differences between countries in the preva-
lence of AMR depend on multiple factors including levels
of antibiotic consumption, access to clean water, adequate
sanitation, vaccination coverage, the availability of quality
healthcare, and access to high-quality medical products. In-
creasing international travel has played a key role in the
spread of drug-resistant pathogens including but not lim-
ited to MRSA and extended spectrum beta-lactamase
(ESBL) producing Enterobacteriaceae [7–9], increased the
proportion of drug-resistant enteric pathogens causing trav-
ellers’ diarrhoea [10–24], and generally increased the num-
ber of travellers infected by drug-resistant pathogens [25,
26]. Globally, third-generation cephalosporin-resistant
Escherichia coli and Klebsiella pneumonia were estimated
to cause 3.7 million to 6.4 million bloodstream infections,
and 28.9 million to 50.1 million serious infections, and
carbapenem-resistant strains caused 0.4 to 0.5 million
bloodstream infections, and 2.7 to 3.1 million serious infec-
tions in 2014 [27]. In the European Economic Area, five
drug-resistant bacterial infections accounted for an estimate
of 33,110 attributable deaths and 170 DALYs per 100,000
population in 2015, rivalling the combined burden of influ-
enza, tuberculosis and HIV [28]. These numbers fore-
shadow the long-term projected consequences of 10
million deaths annually and an additional 24 million people
forced into extreme poverty by 2030 if no action is taken
against AMR [29–31].
Antimicrobial resistance in the Asia and Pacific
Asia Pacific is highly vulnerable to the threats of AMR. The
challenges that impede the progress in controlling AMR in
APAC are wide-ranging and affect both the low-to-middle-
income countries (LMICs) and high-income countries. The
region is projected to be home to 27 of the world’s 43
megacities by 2030 [32], and these densely populated cities
may serve as huge reservoirs for the spread of drug-
resistant pathogens. This holds particularly true for LMICs
with unplanned urbanisation, creating environments where
sanitation is poor, wastewater management is suboptimal,
and where air pollution causes respiratory conditions that
are often mistakenly treated with antibiotics [1, 32, 33].
Within the region, the WHO South-East Asia (SEA) coun-
tries were postulated to have the highest risk of emergence
and spread of AMR among all WHO regions [34–36], for
which the highly transferable New Delhi metallo-β-
lactamase-1 (NDM-1) is a relatively recent reminder [37].
At the same time, the region grapples with a high incidence
of infectious diseases. China and India alone account for al-
most one-third of the global incidence of rifampicin-
resistant TB. This number does not include yet another
one-third of people infected with TB that are either un-
detected or not captured by national statistics [38]. Patients
in 10 hospitals across India with MDR and XDR bacteria
were 1.57 times and 2.65 times more likely to die as com-
pared to similar susceptible infections [39]. In Thailand, 19,
122 of 45,209 (43%) deaths in nine hospitals across
Thailand were attributed to healthcare-associated infections
due to multi-drug resistance [40].
Antimicrobial Resistance Surveillance Progress
and Challenges
The WHO Global AMR Surveillance System (GLASS)
and Organisation for Animal Health (OIE) global database
on the use of antibiotics in animals were established to en-
able the systematic collection of data globally. By 2018, 9
of 11 WHO SEA region countries and 6 of 27 Western
Pacific Region countries had enrolled into GLASS, but
reporting of surveillance data is limited [41]. Comple-
menting the functions of GLASS and OIE in other parts
of the world are successful regional AMR surveillance
networks such as the European Antimicrobial Resistance
Surveillance Network (EARS-Net), Central Asian and
Eastern European Surveillance of Antimicrobial Resistance
(CAESAR) and Red Latinoamericana de Vigilancia de la
Resistencia a los Antimicrobianos (ReLAVRA) [42].
Although several networks collect data on selected patho-
gens in the region, there are no formal surveillance net-
works dedicated to AMR in APAC [43]. The lack of
standardised and consistent data collection and reporting
processes in APAC signifies a massive gap in the ability to
reliably determine the burden of AMR and impact of inter-
ventions implemented in the region [43, 44]. The
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generation of high-quality data is even more challenging,
particularly in settings with limited laboratory infrastruc-
ture. In these settings, clinicians frequently prescribe antibi-
otics without the support of microbiological results and
diagnostic specimens are mostly submitted from patients in
whom empiric treatments have failed [45], leading to the
generation of small datasets with an over-representation of
AMR isolates. Empirical therapy is practised even in large
“tertiary” hospitals, where the “culture of culturing” among
clinicians is frequently lacking [46]. Also, laboratory proce-
dures and quality assurance may be suboptimal due to non-
compliance to quality control testing recommendations,
resulting in the production of poor quality data [47, 48].
Nonetheless, many efforts have been made to improve the
situation. At the regional level, the commitment to address
AMR was demonstrated by the inclusion of AMR in the
current Association of Southeast Asian Nations (ASEAN)
five-year work programme (2016–2020). The signing of the
Joint Declaration on Action against AMR by the Heads of
States in 2017 and the ASEAN Plus Three Leaders’ State-
ment on Cooperation against AMR (ASEAN Plus Three are
the People’s Republic of China, Japan and Republic of
Korea) in 2018 have also sent a clear signal on the recogni-
tion of a need for regional collaboration against AMR. Based
on the 2017 Joint Declaration, the Philippines, with input
from the other ASEAN Member States is preparing a draft
Strategic Framework that will guide the ASEAN member
states in planning for AMR control. The Strategic Frame-
work is targeted to be endorsed by the ASEAN Health Min-
isters in the near future and will be followed up by a
monitoring & evaluation framework for progress tracking.
At the national level, countries are making progress,
albeit at varying pace. Timor Leste, a country that has
emerged from a period of political instability and war in
recent years, is at the start of the process in establishing
a surveillance system to understand the impact of AMR
in the country. Although the country’s past has been
characterised by weak microbiology laboratory capacity
and scarcity of data, the Timorese National Health
System has made many efforts in the past few years to
improve infrastructure and human resources in micro-
biology diagnostics and bring together the relevant
stakeholders to implement a multi-centric surveillance
system by 2019. The progress thus far includes the intro-
duction of antimicrobial susceptibility testing for clinical
bacteria isolates and a closer working relationship be-
tween the Laboratorio Nacional de Saude and National
Hospital to incorporate microbiology diagnostics into
daily clinical decisions as well as to capture trends of
infections and AMR [49]. The collaboration has also
generated early evidence indicative of more widespread
Gram-negative bacteria AMR in Timor Leste [50].
In contrast, Indonesia, the fourth most populous coun-
try in the world, is transitioning from the early phase of its
efforts against AMR that started in 2017. Guidelines for
surveillance have been developed but not fully imple-
mented across the country, and quality data and analyses
are far and few [51]. Nonetheless, the country is in the
process of nominating a National Reference Laboratory
(NRL) and National Coordinating Centre under the lead-
ership of the Committee of AMR Control. So far, the
committee has performed several surveys for ESBL- pro-
ducing E. coli and K. pneumonia and other pathogens
from blood and urine specimens, and antimicrobial usage
(AMU) from hospital prescription in 2016 and 2017.
There are opportunities for capacity building through the
establishment of external quality assurance and profi-
ciency test in the NRL, and extension of the surveys to the
broader network of hospitals including 20 national and
province-level referral hospitals, and 100 regional-level re-
ferral hospitals. It was also highlighted that the develop-
ment of guidelines and tools for prescription review would
help to raise awareness of AMR and guide decision mak-
ing to reduce the rate of empirical therapy in Indonesia.
In addition to strengthening AMR surveillance for human
health, countries such as Myanmar and Singapore are mak-
ing progress in incorporating a multisectoral approach in
tackling AMR. In Singapore, the National Strategic Action
Plan overseen by the AMR Coordinating Office emphasises
a One Health approach for education and training, surveil-
lance and risk assessment, and research. In Myanmar, a
multisectoral approach combining the expertise of epidemi-
ologists, infectious disease clinicians and social scientists to
perform research studies and facilitate translation of evi-
dence to policy for AMR is underway.
Opportunities for antimicrobial resistance surveillance in
the Asia and Pacific
There are several opportunities to improve the capacity for
AMR surveillance in the region as a result of new funding
streams and technological breakthroughs, building on the
foundation laid by past efforts in respective countries and
commitment by international and regional bodies. This sec-
tion briefly covers the potential of technology such as
whole-genome sequencing (WGS) before a more extensive
discussion on technology in the last section on Innovations
to Fight Antimicrobial Resistance.
New funding streams such as the Fleming Fund aim to
collate existing AMR data from the laboratories in the
region and work prospectively in Indonesia, Laos, Papua
New Guinea, Timor-Leste, and Vietnam to build human
and laboratory capacity in order to facilitate WHO
GLASS data submission [52]. It will augment prior and
existing efforts by organisations such as the Wellcome
Trust which is supporting many research programmes
on AMR in the region, including the development of
methods to improve the calculation of drug-resistant in-
fection mortality. Two such methods include:
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 The “AutoMated tool for Antimicrobial resistance
Surveillance System” (AMASS) application to enable
local hospitals to perform data analysis, generate
report and share data [53].
 A patient-focused surveillance tool through the “A
Clinically-Oriented antimicrobial Resistance surveil-
lance Network” (ACORN) to supplement existing
pathogen-focused surveillance systems.
On the technology front, the increasing affordability of
WGS presents an opportunity to enhance surveillance ef-
forts by using molecular epidemiology data to map out the
evolution, spread and transmission of antibiotic-resistant
genes and drug-resistant pathogens. Previous studies that
used WGS on K. pneumoniae and Shigellae spp. [54, 55]
showed that real-time genetic characterisation could be in-
corporated into current surveillance programmes to investi-
gate, inform and potentially intervene during outbreaks.
These studies have paved the way for the use of WGS on
other drug-resistant pathogens such as CRE [56]. Work in
this area has been initiated by research groups in Singapore
who performed WGS on clinical and surveillance CRE iso-
lates collected from 6 public hospitals and the results have
revealed diverse strain types and transmission clusters in
Singapore. It also demonstrated the potential to apply
WGS to investigate the contribution of plasmids and bac-
terial strains separately to the transmission of CRE through
potential reservoirs, as well as generate molecular data to
support conventional epidemiological investigations [57].
Using a One Health approach, samples could be collected
from farm to market/restaurant and sequenced to gain in-
sights into the transmission of drug-resistant genes and bac-
teria from live animals to meat and cooked food, and thus
further understand the ecological drivers of AMR. The pro-
jects involving WGS will require considerable IT infrastruc-
tural investment to process, store and handle a large
amount of data; develop cloud-based solutions and visual
interface for data sharing; and statistical and bioinformatics
expertise for data analysis. It also currently faces challenges
in not having an international standardised protocol for
sample and data processing, dedicated funding and
personnel, and consensus for open communication as well
as sharing of samples and data within and beyond countries.
Lastly, building on efforts within countries and acknow-
ledgement of the importance of collaboration with
international and regional bodies, stakeholders and policy-
makers should consider forming a dedicated organisation
like a regional Centre for Disease Control and Prevention
(CDC). The significant progress achieved by the European
CDC and African CDC, including the organisation of the
EARS-Net and European Surveillance of Veterinary Anti-
microbial Consumption (ESVAC), and launch of the AMR
framework to direct efforts and resources to the threats of
AMR in Africa, are exemplary of successful regionally
coordinated efforts [58, 59]. While signs of progress have
been encouraging, the data collection process in APAC
could be better coordinated to ensure a comprehensive
evaluation of the impact and status of AMR in the region
[41, 60]. A regional CDC could provide the focal point to
facilitate, support and elevate the AMR agenda above the
national level, and help countries to achieve global health
targets more effectively.
Box 1 Issues, recommendations and target outcomes to
improve surveillance on AMR in the APAC
Issues Recommendations Target Outcomes
Weak health
systems
• Increase country
capability and capacity
to reliably detect the
priority pathogens, and
link laboratory results to
clinical outcome.
• Prescribe microbiological
culture (particularly,
blood and urine)
appropriately.
• Report case-based sur-
veillance report, together
with evaluating attribut-
able mortality rate for
AMR.
Improved capacity and
capability to diagnose,
treat and prevent AMR at
all levels of the health
system.
Unclear burden
of AMR
• Improve surveillance to
better describe the
burden of AMR.
• Better capture and
report records of deaths
and other clinical
outcomes attributable to
AMR.
• Develop robust models
that are practical and
acceptable to
policymakers and
healthcare providers.
Ability to monitor and
evaluate the effects of
interventions, and project
the impact of AMR using
modelling options.
Lack of formal
network to
address AMR
• Engage policymakers to
consider developing an
official network for AMR
in the region, based on
role models developed
by European CDC,
African CDC and
European Medicines
Agency, such as EARS-
NET and ESVAC.
Consolidation of resources
and efforts across
countries to deliver
impactful programme at
the regional level.
Lack of open-
access data for
global sharing
• Engage with
policymakers to make
data open-access, such
as AMU and AMR sur-
veillance data.
• Improve the
understanding and
utilisation of all
surveillance data to
decide on resource
allocation for
interventions and to
inform the
implementation of
action plans.
Robust and reliable data
to support further policy
engagement, monitoring
and evaluating impact of
interventions, and
research and
development.
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Drivers and Levers of Antimicrobial Resistance in
the Asia and Pacific
The emerging economies and growing prosperity in
APAC will likely exacerbate the trend of AMR. The
growth in wealth may lead to an increase in demand
for animal protein and the shift to large-scale farming
in countries such as China and India which are pro-
jected to double antibiotic consumption by 2030 [61].
This trend will be compounded by an increase in
purchasing power and access to antibiotics, including
new and second-line antibiotics that are expensive [1,
62]. Furthermore, travel to and from APAC is in-
creasing rapidly [63] associated with an increasing in-
flux of drug-resistant pathogens [64]. Non-existent
antibiotic stewardship for animal health and wastewa-
ter management also contribute significantly to the
spread of AMR [35, 43, 65–67].
At the population level, the accrual of risks of drug-
resistant infections is not readily perceived by individ-
uals, and at the individual level, the risk of misuse of an-
tibiotics is often overlooked in favour of the potential
benefit of recovery from illnesses. For this reason, AMR
is often called the “invisible threat”. The AMR risk is
further compounded by the lack of awareness of appro-
priate antibiotic usage. In 2015, a study by WHO re-
vealed widespread antibiotic use across countries, with
varying levels of understanding of the appropriate util-
isation of antibiotics, and poor understanding of the po-
tential consequences of AMR arising from the misuse of
antibiotics in the majority of the respondents [68].
Antibiotics taken without prescription ranged from 9
to 62% in APAC [69]. In Indonesia, almost three-
quarters of respondents believe antibiotics could treat
colds and flu, and in China, more than half of the re-
spondents reported taking antibiotics in the past six
months with 5% of these antibiotics purchased online.
These observations are supported by other studies, in-
cluding one in Australia where consumers visiting phar-
macies were misinformed about the role of antibiotics in
the treatment of URTIs and other ailments, with over
one third believing that antibiotics would cure cold and
flu faster [70]. These responses were also found to be re-
lated to the propensity for patients to self-diagnose [70].
Due to the increasing public demands for antibiotics,
even in outpatient settings, the health care community
in Asia increasingly prescribes antibiotics, even if
inappropriate, further exacerbated by the absence or
weak enforcement of policies for antibiotic stewardship
[71, 72]. In Malaysia, private clinics contributed to 87%
of the total quantity of antibiotics prescribed in primary
care, and the bulk of the prescriptions was given
unnecessarily for conditions such as URTI, acute
bronchitis, acute gastroenteritis and asthma [73]. The
high prescription rate of antibiotics in private clinics was
attributed to the tendency for general practitioners to
give in to patient’s demand for antibiotics, financial
incentives from the sales of the medication, and the lack
of understanding of the effectiveness of antibiotics
against viral infection such as URTI [73, 74]. The problem
is similar in Cambodia, where village physicians,
pharmacists and unofficial drug suppliers contribute to
unnecessary use of antibiotics [75] due to the preference
for the habitual practice of empirical therapy [76], and to
compensate for poor infection control [77].
Such practices of self-medication and empirical ther-
apy are driven mainly by poor understanding of the
cause of conditions such as UTIs and the association be-
tween antibiotic use and AMR. At the same time, health
systems in countries such as Singapore and Japan strug-
gle with increasing ageing and immunocompromised
populations that are more vulnerable to infections and
correspondingly prescribed more antibiotics. The para-
dox of excessive use of antibiotics and timely access to
antibiotics, however, is more prominent in LMICs. The
restriction in the use and increase in access to antibi-
otics, without proper adaption to the local contexts, may
have a detrimental effect on the control of infectious dis-
eases and AMR [78].
Public health campaign and regulatory response
The WHO acknowledged the challenges relating to poor
awareness and knowledge of AMR in the WHO Global
Action Plan and is leading this front through the World
Antibiotic Awareness Week that occurs in November
every year [79]. In 2018, the campaign took place in
almost all countries in APAC in the form of advocacy
activities through mass media and outreach events,
education programmes through seminars, rallies and
workshops, and creative outlets such as dance
competitions and art exhibitions [80].
In addition to health literacy, other socio-behavioural
determinants include cultural beliefs and the use of tech-
nology. Past studies have found that Asians were more
optimistic about disease risks and held stronger fatalistic
beliefs about prevention than the European and Ameri-
cans, potentially explaining the weaker adherence of
Asians to prevention recommendations [81]. This sug-
gests a greater need for Asian health campaigns to
effectively convey the importance of preventative behav-
iours such as vaccinations and compliance with proper
utilisation of antibiotics. In countries where information
and communication technology has permeated the daily
lives of its citizens, social media and online influencers
are potential nodes for the dissemination of health infor-
mation. Also, networks and consultations with health-
care professionals could be leveraged to promote
appropriate health-seeking behaviours [82]. Such “agents
of change” and platforms could be harnessed to deliver
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public health campaigns and interventions that are cul-
turally relevant and relatable to the target populations.
At this stage, many AMR campaigns are in the early
phases, and few initiatives have been taken to scientific-
ally measure and assess the effectiveness of the commu-
nication strategies. Such evaluation is essential to inform
future campaigns and complement them with more in-
depth studies of antibiotic utilisation attitudes and be-
haviours amongst specific populations as well as pro-
viders in diverse settings.
The effectiveness of public health campaigns could
also be augmented by policy implementation to control
the use of antimicrobials where feasible. This may
include introducing a requirement for a prescription to
buy antibiotics, delinking the prescription and sales of
antibiotics to remove financial incentives in the
healthcare and food-producing sectors [83–86], and to
eventually follow the lead of the European Union which
has banned the use of antibiotics for animal growth pro-
motion since 2006 [87]. The US is moving in the same
direction, and China will ban the use of antimicrobials
for animal growth promotion in aquaculture by 2020
[88]. However, most countries have yet to impose such
regulations, and many countries are still at the stage of
drafting action plans which will require political will and
resources to bring them to reality.
Economic analyses to strengthen the call for action
against antimicrobial resistance
The ability to estimate the financial impact of AMR is
essential to justify investment for interventions,
especially in LMICs where insufficient resources and
competing demands exist. However, current projections
of the economic impact of AMR rely greatly on
simplified assumptions and data inputs due to limited
data on AMR [31, 89, 90]. Many other economic studies
have primarily used hospital data on direct costs for
treatment, diagnosis and hospitalisation [91], limiting
the study of the financial impact of AMR to the hospital
setting. Even so, quantifying the excess cost of drug-
resistant infections in the hospital setting has proven to
be difficult as the use of different methodologies in dif-
ferent studies has generated a broad range of excess
costs ranging from hundreds to hundreds of thousands
of US dollars per patient. Any projection should also be
used with caution considering methodological limita-
tions such as external validity due to the heterogeneity
in caseloads, care patterns, study populations and patho-
gen distribution across the populations [91–93].
More importantly, hospital data does not account for
the pervasive impact AMR has on society and the future.
A broader assessment including the loss of productivity
due to morbidity and mortality arising from AMR, loss
of revenue in travel and trade due to fear of infections
[94], reduction of productivity and wellbeing due to a
reluctance for high-risk medical procedures, and the fi-
nancial consequence of general adverse psychological ef-
fects such as panic on the health and wellbeing of the
population should be considered. The increasing preva-
lence of AMR and possible reversion to the pre-
antibiotic period when infectious diseases are more
deadly and invasive procedures such as elective surgery
are more dangerous to perform should also be factored
into the calculation of the global cost of AMR [95].
Box 2 Vaccination in the War Against AMR
By reducing the need for antibiotics, vaccines may reduce the
prevalence and hinder the development of resistant strains. Introduction
of a conjugate pneumococcal vaccine for infants in the US in 2000 saw
a 57% decline in invasive disease caused by penicillin-resistant strains
and a 59% decline in strains resistant to multiple antibiotics by 2004
across a broad age range - 81% among children under 2 years of age
and 49% among persons aged 65 years and older [96]. Similarly, in
Korea, the serotypes covered by the 7-valent pneumococcal conjugate
vaccine (PCV7) was reported to show a 9.3% decline in resistance to cef-
otaxime and 11% decline in multi-drug resistance after the introduction
of the vaccine in the period 2004 to 2008, as compared to the period
before between 1996 to 2003. In contrast, the serotypes not covered by
PCV7 showed an increase in resistance to cefotaxime by 9.5% and multi-
drug resistance by 15.6% [97]. These results highlight the potential of
using existing vaccines and developing new vaccines to tackle AMR.
Vaccines against viruses such as influenza or dengue also have a role to
play as it reduces the incidence of viral infections that are often mis-
takenly treated with antibiotics. So far, there have been few studies that
quantify the effect of vaccines on AMR dynamics, suggesting a gap
which could be filled by mathematical models to understand the impact
of vaccination on the transmission of drug-resistant pathogens [98].
Innovations to Fight Antimicrobial Resistance
Innovations in diagnosis and surveillance of antimicrobial
resistance
The earlier section Antimicrobial Resistance Surveillance
touched on the potential of technology such as WGS to
understand the transmission dynamics of drug-resistant
genes and pathogens and highlighted the potential for new
therapeutic, diagnostic and surveillance innovations to
bolster the fight against AMR.
One of the most promising areas in which
technological innovations can be used to tackle AMR is
to minimise empirical therapy, which has contributed to
the unnecessary prescription of antibiotics for viral
infections such as URTI. Among the factors promoting
the practice of empirical therapy is the lack of affordable
and simple point-of-care (POC) diagnostics that can dis-
tinguish bacterial from other infections and readily de-
termine the antimicrobial susceptibility for the former.
A variety of approaches to developing novel POC diag-
nostic tools have emerged to increase the throughput,
speed, and cost-effectiveness to diagnose infectious dis-
eases and determine the antibiotic susceptibility profile.
Recent new developments include the combination of
microfluidics to integrate DNA and RNA extraction, and
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PCR amplification with technologies such as micro-
optics to create optofluidic platforms to enable single-
cell analysis and pathogen identification [99, 100]. An-
other success is the development of ultra-fast
microfluidics-based chips that work with low number of
cells for liquid-phase DNA/RNA purification and subse-
quent PCR amplification in a few minutes [101, 102].
These have the potential for customisation of infectious
disease panels that correspond to different disease bur-
dens in different parts of the world.
The application of engineering design principles to create
affordable, fast, and accurate medical diagnostics is also
gaining prominence [103–105]. This is illustrated in the
application of the principles of immunochromatographic
rapid diagnostic tests in over-the-counter pregnancy tests
to create affordable POC diagnostics for infectious disease
[103]. Given the problems of thermal denaturation and
nonspecific binding events that occur with antibody-based
tests, robust affinity reagents based on thermostable protein
scaffolds can be complemented with systematic approaches
to enhance assay sensitivity and ease-of-use [103–105].
Another potential development that could complement
pathogen-specific tests is the use of systems-level “omic”
analyses that profile host-derived response markers that
are predictive of the infections. Initial successes in using
integrated omic analyses to identify human biomarkers
have been shown in studies that accurately differentiate
sepsis from systemic inflammation [106], differentiate
mild and severe forms of dengue infection [107], and pre-
dict host-pathogen interactions [108].
Innovations in pre-clinical and regulatory science to
reduce antimicrobial development costs
In addition to diagnostics and surveillance, innovative
approaches could also help to overcome the barriers in
developing new drugs. The high cost of research and
development and uncertainties in the return of investments
have caused most large pharmaceutical companies to
abandon development of new antimicrobials [109, 110],
shifting the challenge to academic researchers and smaller
biotechnology and pharmaceutical companies. One of the
ways to reduce the cost of development is to reduce the
development timeline by borrowing lessons learnt from
biological therapeutics. This includes a two-pronged
approach involving the multiplexing of pre-clinical and po-
tentially clinical analytics with “omics” technologies, and
dovetailing drug discovery, development, and manufactur-
ing processes [111]. The combination of these efforts has
the potential to reduce the timeline, and thus the cost, for
pre-clinical development of a new antimicrobial agent from
years to months. Similar innovations in manufacturing and
other processes [112], as well as approaches to drug discov-
ery such as repurposing [113], may further reduce the costs
of the development phase and promote existing efforts to
incentivise investments in new antimicrobials [114].
Innovations in studying and manipulating the human
microbiome for AMR diagnosis and treatment
Understanding of the human microbiome as being
important in the establishment of reservoirs of drug-
resistant pathogens is emerging [115, 116]. The micro-
biome is also a potential target for novel approaches to
controlling AMR [23, 117–122]. This is most apparent in
the technological innovations that are advancing our un-
derstanding of the role of the human microbiome in both
acquiring and combating AMR [123, 124]. These innova-
tions are driven by the goals of not only identifying and
quantifying each of the thousands of types of bacteria,
bacteriophages, and other organisms in each human
organ, but also of culturing and storing the isolated organ-
isms, some of which are fastidious anaerobes.
The latter problem is being addressed by a team of
scientists that founded the Global Microbiome
Conservancy, which has the goal of culturing and
sequencing more than 10,000 bacterial strains from the
human gut in populations from more than 30 countries
(http://microbiomeconservancy.org). Building on an
initial collection of 7600 gut bacterial isolates and their
genomes from healthy and urban North Americans, the
Global Microbiome Library expanded the collection with
more than 4000 additional strains from under-
represented populations in Arctic regions, and East and
Central Africa. Defining the genomic sequences and the
presence of AMR genes in this growing strain collection
has relied on recent innovations in WGS technology,
while the identification of sequences of individual mi-
crobes among the thousands in a single faecal DNA
sample requires even more sophisticated sequencing
innovations, such as epicPCR for profiling genetic traits
such as AMR [125]. By necessity, these sequencing
innovations are being matched with computational
innovation for assembling and mining genomes of gut,
skin, and other microbial communities, including identi-
fying and quantifying AMR genes [126].
One of the success stories arising from innovations in
microbiome science has been the use of faecal
microbiome transplants (FMTs) to treat chronic, drug-
resistance infections by Clostridium difficile. Overgrowth
of this anaerobic, sporulating, Gram-positive bacillus fol-
lowing the use of broad-spectrum antibiotics for treating
other infections has become a major health threat in the
past two decades with the emergence of a particularly
virulent strain of C. difficile [127]. Previously treatable
with a variety of antibiotics, 25% of C. difficile infections
relapse one or more times and require multiple pro-
longed courses of metronidazole or vancomycin. How-
ever, FMTs have proven curative in up to 90% of
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relapsed cases in several studies [127], presumably by re-
populating the gut with a “healthy” set of microbes that
outcompete the C. difficile. This same approach can po-
tentially be explored for AMR, with FMT as a major
therapeutic tool in de-colonising intestinal carriage of
drug-resistant genes and bacteria [128].
Box 3 Innovations to address AMR
Surveillance:
• Harmonise sample and data collection procedures and enable access
to samples and data for testing and mining.
• Adopt molecular epidemiology using whole-genome sequencing to
complement phenotypic studies for transmission dynamics.
Diagnostics:
• Develop rapid diagnostic or point-of-care diagnostics for quick identi-
fication of pathogens and antimicrobial susceptibility.
• Develop non-pathogen-based approaches that exploit human re-
sponse signatures to complement existing pathogen-targeted
technologies.
Therapeutics:
• Collaborate with regulatory agencies to shorten the timeline for drug
development at all stages, from target discovery to clinical trials, thus
reducing the cost of developing new AMR therapeutics.
• Develop new vaccine and antibiotic pipelines, and explore innovative
approaches such as immunotherapy, phage therapy, drug repurposing,
and combination therapy.
Conclusion
Three recurring themes emerge from the discussions
above. The first is that there is no single solution or path to
AMR control in the region, given the socioeconomic and
cultural diversity within APAC, rapid changes in the region,
and the multifaceted nature of the challenges of AMR. The
second is the need for multisectoral and One Health
approaches to synergise the efforts and harness the
expertise and experiences in surveillance, sociobehavioural,
economics and innovations. The third is the value of inter-
country collaborations in the region and the necessity to
elevate the issue of AMR control beyond just national
agendas. After all, progress achieved in one country could
be off-set by failures in another country. It is an opportune
time to put together a regionally coordinated effort that is
target-driven, sustainable, and builds on a framework that
facilitates communication and consistent governance to
strengthen the fight against AMR.
Contribution to existing literature
This report neither provides an extensive review of
AMR in the region which has been captured
exceptionally well in existing literature [35, 43] nor
covers AMR in the context of topics such as financing
and global health security. Nonetheless, it adds to
existing literature the voices of people across the region
who work in infectious disease control, advocacy and
research. These people shared the recognition of the
growing threat of AMR and the keen interest in
promoting the agenda of AMR by bringing to wider
attention the issues and drivers of AMR and garnering
support and coordination within and beyond institutions
and countries.
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